A study to evaluate the angiogenesis polymorphisms (hypoxia inducible factor 1, vascular endothelial growth factor) profile in patients with advanced hepatocellular carcinoma treated with sorafenib.
Phase of Trial: Phase IV
Latest Information Update: 02 Sep 2015
At a glance
- Drugs Sorafenib (Primary)
- Indications Liver cancer
- Focus Biomarker; Therapeutic Use
- 02 Sep 2015 New trial record